Interferon Alfa-2A

CHEMBL2108508 Phase 4 Đã phê duyệt Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This recombinant protein is a type of interferon used to treat various cancers and viral infections by modulating the immune system and inhibiting cell growth. It has been used for hairy cell leukemia, chronic myelogenous leukemia, melanoma, and chronic hepatitis C and B. It is administered by injection and commonly causes flu-like symptoms.

Lĩnh vực điều trị

Cơ chế tác dụng

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This recombinant protein is a type of interferon used to treat various cancers and viral infections by modulating the immune system and inhibiting cell growth. It has been used for hairy cell leukemia, chronic myelogenous leukemia, melanoma, and chronic hepatitis C and B. It is administered by injection and commonly causes flu-like symptoms.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Interferon Alfa-2A is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108508. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.